Sumita Paul, MD, MPH, MBA

Chief Medical Officer and Senior Vice President of Research & Development

Sumita Paul

Sumita Paul, MD, MPH, MBA, joined Lakewood-Amedex in 2021 and is the company’s Senior Vice President, Research and Development, and Chief Medical Officer. In this role, Dr. Paul oversees clinical development, drug development, CMC, regulatory, preclinical, global clinical operations, drug safety, biometrics, pre-commercialization, and other related functions and is responsible for developing and driving execution of Lakewood-Amedex’s clinical development programs.

 

Dr. Paul completed her Residency and Clinical Fellowship from Massachusetts General Hospital, Harvard Medical School, and became Board Certified in Internal Medicine. She has formal training in Epidemiology and Biostatistics from Harvard University where she completed her Master of Public Health Degree. Her interest in healthcare entrepreneurship led her to Wharton Business School for her MBA degree.

 

She has extensive leadership experience in research and clinical trials at Harvard, in academia, big pharma, and small biotech. She has over 30 years of combined leadership experience as program lead in clinical research & phase 1-4 clinical trials, clinical medicine and disease prevention, microbiome research, CMC & regulatory strategies, business development and commercialization.

 

Experienced in leading drug development for multiple therapeutic areas including rare diseases, cardiac, lipids, diabetes, neurology, and infectious diseases (with BARDA funding). Successful experience in managing cross-functional teams, and program leadership for high priority early and late stage development projects. Most recently as Global Head of Clinical Development, Rare Diseases; Program Lead for Pemziviptadil and PB6440 (angiotensin synthase inhibitor) at PhaseBio.

 

Dr. Sumita Paul’s previous experience at Summit Therapeutics includes a leadership role as Vice President, Medical, lead in microbiome sparing precision novel antibiotic development for C. difficile infection, Ridinilazole, evaluating colonization resistance and sparing of secondary bile salts as a mechanism for preventing infectious disease recurrence in a superiority trial. As a C. difficile survivor, she is a passionate patient advocate for antibiotic stewardship and use of precision antibiotics for curbing antimicrobial resistance without perturbation of the gut microbiome.